Recently, using immunohistochemistry, Arl4c was identified as a biomarker for a worse prognosis and a novel therapeutic target in endometriosis-associated ovarian cancer (Wakinoue et al., 2019). This evidence concerns the gene ARL4C and ovarian cancer.